Table F15Association between blood levels of lipids, proteins, sex hormones, and mitogenes with DCIS

StudyComparison Categories: Estimate (95% CI)
Blood lipids
Elkhadrawy, 199867
Design: Case control study
Source: Cancer Center Registry (NY)
Serum cholesterol > vs. <200mg/dL: 1.66 (1.07; 2.58) (OR)
Serum cholesterol > vs. <200mg/dL: 1.15 (0.71; 1.87) (OR)
Serum cholesterol >236 vs. 72–166mg/dL: 1.89 (0.88; 4.08) (OR)
Serum cholesterol 167–207 vs. 72–166mg/dL: 1.83 (0.86; 3.88) (OR)
Serum cholesterol 208–235 vs. 72–166mg/dL: 1.1 (0.49; 2.48) (OR)
Blood proteins
Elkhadrawy, 199867
Design: Case control study
Source: Cancer Center Registry (NY)
Serum albumin: 3.16 (1.82; 5.51) (OR)
Serum albumin >4.7 vs. 1.7–3.11: 9.2 (3.24; 26.14) (OR)
Serum albumin 4.4–4.6 vs. 1.7–3.10: 9.52 (3.57; 25.4) (OR)
Serum albumin 4–4.3 vs. 1.7–3.9: 4.4 (1.63; 11.85) (OR)
Sex hormones
Zeleniuch-Jacquotte, 200580
Design: Nested (New York University
Women’s Health Study) Case control study
Source: Women’s Health Study (NY)
DHEAS 1: 1 (1; 1) (OR)
DHEAS 2: 0.8 (0.34; 1.87) (OR)
DHEAS 3: 0.84 (0.35; 2.03) (OR)
Androstenedione 1: 1 (1; 1) (OR)
Androstenedione 2: 1.79 (0.8; 3.99) (OR)
Androstenedione 3: 0.94 (0.41; 2.14) (OR)
Estradiol 1: 1 (N/A; N/A) (OR)
Estradiol 2: 1.17 (0.53; 2.57) (OR)
Estradiol 3: 0.94 (0.4; 2.23) (OR)
Estrone 1: 1 (N/A; N/A) (OR)
Estrone 2: 1.83 (0.79; 4.23) (OR)
Estrone 3: 1.02 (0.42; 2.48) (OR)
SHBG 1: 1 (1; 1) (OR)
SHBG 2: 0.89 (0.41; 1.91) (OR)
SHBG 3: 1.01 (0.45; 2.3) (OR)
Testosterone 1: 1 (1; 1) (OR)
Testosterone 2: 1.01 (0.43; 2.38) (OR)
Testosterone 3: 1.14 (0.44; 2.94) (OR)
Mitogenes
Bohlke, 199868
Design: Case control study
Source: Cancer Registry (MA)
High risk: women with IGF-I values in the upper two control-defined tertiles and IGFBP-3 values in the lowest control-defined tertile: 3.7 (1.1; 12.2) (OR)
IGFBP-3 (ng/ml) >3,493.4 vs. <3,239.4: 0.7 (0.3; 1.7) (OR)
IGFBP-3 (ng/ml) <3,239.4 (reference group): 1 (1; 1) (OR)
IGFBP-3 (ng/ml) 3,239.5–3,493.4 vs. <3,239.4: 0.4 (0.2; 1) (OR)
IGF-I (ng/ml): >175.5 vs. <121.5: 1.8 (0.7; 4.6) (OR)
IGF-I (ng/ml): <121.5 (reference group): 1 (1; 1) (OR)
IGF-I (ng/ml): 121.6–175.5 vs. <121.5: 2.4 (1; 5.6) (OR)
IGF-I/IGFBP-3 ratio second vs. first tertile: 1.8 (0.8; 4.2) (OR)
IGF-I/IGFBP-3 ratio third vs. first tertile: 1.6 (0.7; 3.8) (OR)
Intermediate risk: all other women: 1.8 (0.6; 5.3) (OR)
Low risk: women with IGF-I values in the lowest tertile and IGFBP-3 values in the upper two tertiles: 1 (1; 1) (OR)

From: Appendix F, Evidence Tables

Cover of Diagnosis and Management of Ductal Carcinoma in Situ (DCIS)
Diagnosis and Management of Ductal Carcinoma in Situ (DCIS).
Evidence Reports/Technology Assessments, No. 185.
Virnig BA, Shamliyan T, Tuttle TM, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.